A detailed history of E Fund Management Co., Ltd. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 25,826 shares of TGTX stock, worth $490,952. This represents 0.02% of its overall portfolio holdings.

Number of Shares
25,826
Previous 30,553 15.47%
Holding current value
$490,952
Previous $521,000 24.76%
% of portfolio
0.02%
Previous 0.03%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$13.02 - $21.3 $61,545 - $100,685
-4,727 Reduced 15.47%
25,826 $392,000
Q4 2023

Feb 06, 2024

SELL
$6.68 - $18.81 $89,892 - $253,126
-13,457 Reduced 30.58%
30,553 $521,000
Q3 2023

Nov 13, 2023

BUY
$8.36 - $26.5 $231,939 - $735,216
27,744 Added 170.56%
44,010 $368,000
Q2 2023

Aug 11, 2023

SELL
$15.48 - $35.0 $172,787 - $390,670
-11,162 Reduced 40.7%
16,266 $404,000
Q1 2023

May 11, 2023

SELL
$10.23 - $19.34 $122,401 - $231,403
-11,965 Reduced 30.37%
27,428 $413,000
Q4 2022

Feb 14, 2023

SELL
$5.01 - $11.83 $68,922 - $162,745
-13,757 Reduced 25.88%
39,393 $466,000
Q3 2022

Nov 14, 2022

SELL
$4.57 - $8.4 $77,484 - $142,422
-16,955 Reduced 24.19%
53,150 $315,000
Q2 2022

Aug 15, 2022

BUY
$3.74 - $10.66 $148,186 - $422,370
39,622 Added 129.98%
70,105 $298,000
Q1 2022

May 12, 2022

BUY
$7.81 - $20.45 $156,332 - $409,347
20,017 Added 191.26%
30,483 $290,000
Q4 2021

Feb 11, 2022

BUY
$15.2 - $35.51 $116,796 - $272,858
7,684 Added 276.2%
10,466 $199,000
Q1 2021

May 12, 2021

BUY
$41.61 - $54.3 $115,759 - $151,062
2,782 New
2,782 $134,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $2.76B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.